Bartlett DL - Search Results

1

Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963.

Thorne SH, Hwang TH, O'Gorman WE, Bartlett DL, Sei S, Kanji F, Brown C, Werier J, Cho JH, Lee DE, Wang Y, Bell J, Kirn DH. Thorne SH, et al. Among authors: bartlett dl. J Clin Invest. 2007 Nov;117(11):3350-8. doi: 10.1172/JCI32727. J Clin Invest. 2007. PMID: 17965776 Free PMC article.

2

Oncolytic Virotherapy and the Tumor Microenvironment.

Berkey SE, Thorne SH, Bartlett DL. Berkey SE, et al. Among authors: bartlett dl. Adv Exp Med Biol. 2017;1036:157-172. doi: 10.1007/978-3-319-67577-0_11. Adv Exp Med Biol. 2017. PMID: 29275471 Review.

3

The use of oncolytic vaccinia viruses in the treatment of cancer: a new role for an old ally?

Thorne SH, Bartlett DL, Kirn DH. Thorne SH, et al. Among authors: bartlett dl. Curr Gene Ther. 2005 Aug;5(4):429-43. doi: 10.2174/1566523054546215. Curr Gene Ther. 2005. PMID: 16101516 Review.

4

First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity.

Zeh HJ, Downs-Canner S, McCart JA, Guo ZS, Rao UN, Ramalingam L, Thorne SH, Jones HL, Kalinski P, Wieckowski E, O'Malley ME, Daneshmand M, Hu K, Bell JC, Hwang TH, Moon A, Breitbach CJ, Kirn DH, Bartlett DL. Zeh HJ, et al. Among authors: bartlett dl. Mol Ther. 2015 Jan;23(1):202-14. doi: 10.1038/mt.2014.194. Epub 2014 Oct 8. Mol Ther. 2015. PMID: 25292189 Free PMC article. Clinical Trial.

5

Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects.

Sampath P, Li J, Hou W, Chen H, Bartlett DL, Thorne SH. Sampath P, et al. Among authors: bartlett dl. Mol Ther. 2013 Mar;21(3):620-8. doi: 10.1038/mt.2012.257. Epub 2012 Dec 11. Mol Ther. 2013. PMID: 23229093 Free PMC article.

6

Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer.

Li J, O'Malley M, Urban J, Sampath P, Guo ZS, Kalinski P, Thorne SH, Bartlett DL. Li J, et al. Among authors: bartlett dl. Mol Ther. 2011 Apr;19(4):650-7. doi: 10.1038/mt.2010.312. Epub 2011 Jan 25. Mol Ther. 2011. PMID: 21266959 Free PMC article.

7

Expression of CCL19 from oncolytic vaccinia enhances immunotherapeutic potential while maintaining oncolytic activity.

Li J, O'Malley M, Sampath P, Kalinski P, Bartlett DL, Thorne SH. Li J, et al. Among authors: bartlett dl. Neoplasia. 2012 Dec;14(12):1115-21. doi: 10.1593/neo.121272. Neoplasia. 2012. PMID: 23308044 Free PMC article.

8

Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene.

Chalikonda S, Kivlen MH, O'Malley ME, Eric Dong XD, McCart JA, Gorry MC, Yin XY, Brown CK, Zeh HJ 3rd, Guo ZS, Bartlett DL. Chalikonda S, et al. Among authors: bartlett dl. Cancer Gene Ther. 2008 Feb;15(2):115-25. doi: 10.1038/sj.cgt.7701110. Epub 2007 Dec 14. Cancer Gene Ther. 2008. PMID: 18084242 Free PMC article.

9

Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy.

Puhlmann M, Gnant M, Brown CK, Alexander HR, Bartlett DL. Puhlmann M, et al. Among authors: bartlett dl. Hum Gene Ther. 1999 Mar 1;10(4):649-57. doi: 10.1089/10430349950018724. Hum Gene Ther. 1999. PMID: 10094208

10

Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant.

Puhlmann M, Brown CK, Gnant M, Huang J, Libutti SK, Alexander HR, Bartlett DL. Puhlmann M, et al. Among authors: bartlett dl. Cancer Gene Ther. 2000 Jan;7(1):66-73. doi: 10.1038/sj.cgt.7700075. Cancer Gene Ther. 2000. PMID: 10678358

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

410 results

Search Page

Filters